Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study
Top Cited Papers
- 28 July 2016
- journal article
- research article
- Published by Elsevier BV in European Urology
- Vol. 71 (2), 151-154
- https://doi.org/10.1016/j.eururo.2016.07.032
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Long-term Safety and Antitumor Activity in the Phase 1–2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate CancerEuropean Urology, 2015
- Enzalutamide in Metastatic Prostate Cancer before ChemotherapyThe New England Journal of Medicine, 2014
- Abiraterone in Metastatic Prostate Cancer without Previous ChemotherapyThe New England Journal of Medicine, 2013
- Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyThe New England Journal of Medicine, 2012
- Abiraterone and Increased Survival in Metastatic Prostate CancerThe New England Journal of Medicine, 2011
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working GroupJournal of Clinical Oncology, 2008